OR WAIT null SECS
Mehrdad Ghoreishi, MD explores the latest advances in aortic disease treatment and the role of minimally invasive techniques.
In a recent interview with HCPLive, Mehrdad Ghoreishi, MD, the co-director of aortic surgery and medical director of cardiac surgery research at Baptist Health Miami Cardiac & Vascular Institute, discussed the evolving landscape of aortic disease treatment, highlighting the advantages of minimally invasive endovascular techniques compared with traditional open-heart surgery.
Ghoreishi recently presented a session entitled “The Next Frontier: Ascending Aorta and Aortic Valve Therapy” at the International Symposium on Endovascular Therapy (iSET) 2025 in Hollywood, Florida.
While open surgery remains the gold standard for aortic root, ascending aorta, and aortic arch diseases, endovascular approaches offer viable alternatives for patients unable to tolerate major surgery. Ghoreishi detailed the current availability of US Food and Drug Administration (FDA)-approved devices for the descending thoracic and abdominal aorta and the ongoing trials for ascending aorta and aortic arch interventions.
Ghoreishi also underscored the importance of multidisciplinary collaboration in aortic care, emphasizing the role of cardiac surgeons, vascular specialists, interventional radiologists, and cardiologists in optimizing treatment strategies. This team-based approach not only improves surgical planning but also ensures comprehensive follow-up care, enhancing patient outcomes.
Looking ahead, Ghoreishi shared excitement for upcoming advancements in both open and endovascular procedures, including novel stent graft technologies for the aortic arch and ascending aorta. He highlighted the potential of endovascular solutions for high-risk patients, particularly in the context of Type A aortic dissections, where minimally invasive techniques could serve as a bridge to definitive treatment. As the field progresses, he expressed anticipation for significant innovations over the next five years that will expand the scope of endovascular therapy, ultimately transforming the management of complex aortic disease.
Disclosures: Ghoreishi reports no relevant disclosures.
References